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Introduction
The prognosis of systemic lupus erythematosus (SLE)
markedly improved following the introduction of monthly
intravenous pulse cyclophosphamide (500–1000mg/m2).
Nevertheless, despite pulse cyclophosphamide and
advances in supportive care such as new antihypertensive
medications, patients with active SLE involving visceral
organs have 2-year and 5-year mortalities of approximately
20% and 35%, respectively. Since SLE is predominately a
disease of young women, improvements in disease-related
morbidity and mortality were desperately needed.
Autologous hematopoietic stem cell transplant regimens
for patients with cancer are based on dose escalation of
chemotherapeutic drugs that demonstrate effectiveness at
standard dosing. Borrowing this concept from the field of
oncology, we dose escalated cyclophosphamide, the
most effective antilupus medication, to 200mg/kg. Also
borrowing from experience with a hematopoietic stem cell
transplantation (HSCT) conditioning regimen for aplastic
anemia, where T lymphocytes help to sustain the disease
manifestations, a regimen of 200mg/kg cyclophos-
phamide (divided as 50mg/kg over 4 days) and of
90mg/kg equine antithymocyte globulin (ATG) (divided as
30mg/kg over 3 days) was selected.
To collect hematopoietic stem cells, they need to be mobi-
lized into the peripheral blood with either a hematopoietic
colony stimulating factor such as granulocyte-colony stim-
ulating factor or a chemotherapeutic drug such as
cyclophosphamide, or both. Since granulocyte-colony
stimulating factor is a proinflammatory cytokine that by
itself may exacerbate disease, the stem cells were mobi-
lized into the peripheral blood using 2.0g/m2 cyclophos-
phamide, granulocyte-colony stimulating factor beginning
72 hours later, and harvest beginning upon white blood
cell rebound (usually 10 days after cyclophosphamide).
The stem cells are collected on an outpatient basis by
apheresis and then purified in the laboratory by positive
selection using an antibody to CD34, a progenitor cell
antigen, resulting in a 4-log depletion of lymphocytes.
Continuing the analogy to malignancies, HSCT is gener-
ally effective if the cancer is still responsive to chemother-
apy but is ineffective when applied to chemotherapy
refractory disease. Lupus is an immune responsive
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Abstract
Hematopoietic stem cell transplantation was first reported for patients with systemic lupus
erythematosus in 1997. The procedure has since been performed worldwide including in Europe, in
Brazil, and in China. A National Institutes of Health-funded phase III clinical trial of hematopoietic stem
cell transplantation for refractory systemic lupus erythematosus is anticipated to begin in 2003.
Encouraging responses are raising new hope about the role of adult hematopoietic stem cells in
systemic lupus erythematosus.
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disease that, when refractory to oral daily cyclophos-
phamide, responds to dose escalation with intravenous
monthly cyclophosphamide. It was anticipated that SLE,
refractory to monthly pulse cyclophosphamide, might
respond to further dose escalation of cyclophosphamide
and HSCT. These expectations were realized and patients
with refractory disease have entered sustained freedom
from immune suppression for up to 6 years following
HSCT [1–6]. Of 20 patients followed for between
6 months and 6 years post HSCT at Northwestern Univer-
sity, only one is taking more than 10mg/day prednisone.
There are unique aspects to SLE compared with malignan-
cies or other autoimmune diseases treated by HSCT.
Lupus patients are often exposed to chronic high-dose cor-
ticosteroids and are consequently diabetic, hyperlipidemic,
osteoperotic, hypertensive, susceptible to coronary artery
disease, susceptible to avascular necrosis and susceptible
to opportunistic infections. Patients should be screened for
cardiac symptoms, for avascular necrosis and for occult
infection prior to registration. In addition, aggressive antivi-
ral, fungal and bacterial coverage is initiated during any
period of neutropenia independent of fever. After HSCT, as
corticosteroids are gradually withdrawn, the disease
becomes quiescent, SLE-associated immune abnormalities
slowly resolve and the risk of infection, a common cause of
death for patients with SLE, returns to that of normal
healthy controls. Improvement generally occurs gradually
over 6–12 months and an aggressive corticosteroid taper
may precipitate disease flare during this interval.
Organ dysfunction, such as renal or pulmonary insuffi-
ciency, is considered a contraindication for HSCT among
patients with malignancies. For patients with SLE, in con-
trast, since organ compromise is due to lupus, impaired
visceral organ function is not necessarily a contraindica-
tion, and may even be the major indication for HSCT.
While this makes the transplant procedure more compli-
cated, marked organ improvement, particularly of the lung,
the kidney and the central nervous system, has occurred
following HSCT. Patients with nephritis are unusually sus-
ceptible to electrolyte disturbances and to volume over-
load, which may lead to pulmonary edema and to
respiratory failure unless early dialysis is initiated. Pharma-
cokinetics of drugs such as high cyclophosphamide
metabolites are poorly understood in patients with renal
failure. For this reason, in patients with either renal insuffi-
ciency or renal failure, dialysis is performed each morning
after a cyclophosphamide infusion the preceding day.
Besides tapering off immune suppressive medications,
prior to HSCT, some patients required multiple antihyper-
tensive medications, most of which have also been gradu-
ally tapered following transplant. Improvement in
end-organ function has demonstrated remarkable
resilience following HSCT. While end-stage renal fibrosis
would not be expected to reverse, proteinuria resolves and
some patients become dialysis free. Pulmonary function
tests including both forced vital capacity and diffusion
capacity gradually improve. Several patients became free
of supplemental inspired oxygen for the first time in several
years. Serologic measures associated with disease such
as hypocomplementemia, antidouble-stranded DNA, and
antinuclear antibodies normalize. Detection of low titer
antinuclear antibody positivity in the years following trans-
plant seldom predicts reactivation of disease.
With a cyclophosphamide/ATG regimen, hematopoietic
stem cells are not necessary for re-engraftment. While
intensely immune suppressive, the regimen is not mye-
loablative and endogenous hematopoiesis would recover.
The hematopoietic stem cells are infused in order to
shorten the past transplant neutropenic interval by
4–6 days compared with the same dose of cyclophos-
phamide without hematopoietic stem cell support, and
also to hasten stem cell regeneration of the immune
system under the umbrella of the ATG effect.
Based on the same rationale, Brodsky and colleagues at
Johns Hopkins have dose escalated cyclophosphamide to
200mg/kg without ATG or HSCT [7]. Whether transplant
doses of cyclophosphamide are given with or without
hematopoietic stem cell support, impressive responses
are occurring. It is currently impossible to contrast the two
approaches since SLE is a clinically heterogeneous
disease and entry criteria between the two studies are dif-
ferent [3,6,7]. The Hopkins approach has included some
patients never treated with cyclophosphamide and other
patients previously treated with only oral cyclophos-
phamide [7]. The Northwestern HSCT study required
failure of intravenous cyclophosphamide (i.e. active
disease requiring treatment) after a minimum of 3–6 con-
secutive months of cyclophosphamide [2–6]. Both the
Hopkins and the Northwestern protocols are based on
dose escalation of cyclophosphamide. However, due to
mobilization of stem cells with 2.0mg/m2 (approximately
55mg/kg) cyclophosphamide 2–4 weeks prior to HSCT,
patients on the HSCT protocol receive a total cyclophos-
phamide dose of 255mg/kg, compared with 200mg/kg in
the study of Brodsky and colleagues. By having to mobi-
lize stem cells, the transplant protocol allows for infusion
of a significantly higher total cyclophosphamide dose
(along with ATG), resulting in significantly more intense
immune suppression.
For the laboratory immunologist, tolerance is defined as
antigen-specific unresponsiveness. For the clinician, toler-
ance is lack of disease manifestations while off immune
suppressive medications with normally intact third-party
responses. Autologous HSCT appears to be reintroducing
self-tolerance accompanied with a restoration of immune
diversity, although the exact pathway(s) (e.g. T regulatory209
cells, deletion, etc.) are yet to be determined. Two philo-
sophical approaches that do not really define the mecha-
nisms involved in tolerance exist towards autologous
HSCT of autoimmune diseases. One approach is ‘immune
ablation’, advocated by the Seattle Consortium [8]. Advo-
cates of ‘immune ablation’ use the terminology high-dose
immune suppressive therapy. In this view, every potentially
autoreactive lymphocyte is pathologic.
The alternative concept is one of immune ‘reset’ or
immune ‘balance’ [5]. In this notion, autoreactive cells may
be viewed as potentially ‘normal’. During development,
T cells that bind a self-epitope with high avidity undergo
apoptosis [9–11]. However, T cells that fail to recognize a
self-epitope also undergo apoptosis [9–11]. Therefore,
circulating T cells in a healthy person normally possess a
T-cell receptor repertoire selected to a self-epitope.
Immune cells may be viewed as a dynamic equilibrium that
maintains steady state by constantly fluctuating between
tolerance and immunity. This dynamic state is best demon-
strated by the intermittent clinical course of some autoim-
mune diseases such as relapsing-remitting multiple
sclerosis, which flares and remits spontaneously even
without treatment. Using the notion of immune balance,
the conditioning regimen is not intended to destroy every
immune cell, but rather is intended to be sufficient to
restore immune ‘balance’.
In practice, the philosophy of high-dose immune suppres-
sive therapy leads to maximal immune suppressive regi-
mens that have been accompanied by infection-related
mortality as well as regimen-related mortality [12]. In com-
parison, the notion of immune balance leads to less
intense regimens that are more easily tolerated and have
less infection-related risk. Whether one concept or the
other is correct remains unclear. There is currently no data
to support more intense regimens over less toxic regimens
in terms of disease remission or relapse rate. The appro-
priate regimen intensity may vary by disease. For example,
cyclophosphamide with or without ATG appears inade-
quate for complete responses or sustained untreated
partial responses in rheumatoid arthritis [13,14]. Yet this
same regimen appears highly effective in SLE [2–6].
Whatever the most appropriate concept for a given
disease, it is probably prudent to determine outcome with
less intense regimens before testing more intense, and
potentially more toxic, conditioning regimens.
Conclusion
Future studies are being planned to confirm the efficacy of
HSCT for SLE as well as to better understand the mecha-
nisms of disease remission. A National Institutes of Health-
funded phase III trial comparing HSCT with pulse
intravenous cyclophosphamide is in development. If HSCT
is the more effective therapy, the next phase III trial may be
a direct comparison of HSCT with cyclophosphamide and
ATG versus the Hopkins’ treatment protocol incorporating
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